Skip to main content
Top
Published in: Cancer Imaging 1/2024

Open Access 01-12-2024 | Hepatocellular Carcinoma | Research article

HCC portal hypertension imaging score derived from CT predicts re-bleeding and mortality after acute variceal bleeding

Authors: Mingyuan Zhao, Binyue Zhang, Jianqiang Shi, Xiaoxian Tang, Hongxia Li, Shengwen Li, Yunfeng Yang, Yi Han, Rong Wang, Jian Xun, Kai Zhang, Xirun Wu, Jiang Zhao

Published in: Cancer Imaging | Issue 1/2024

Login to get access

Abstract

Background/Purpose

Risk factors for re-bleeding and death after acute variceal bleeding (AVB) in cirrhotic HCC patients are not fully understood.We aimed to (1) explore how the combination of high-risk esophageal varices, HCC status, and portal vein tumor thrombus (i.e., HCC Portal Hypertension Imaging Score [HCCPHTIS]) helps predict increased risk of variceal re-bleeding and mortality; (2) assess predictability and reproducibility of the identified variceal re-bleeding rules.

Methods

This prospective study included 195 HCC patients with first-time AVB and liver cirrhosis, and conducted multivariable Cox regression analysis and Kaplan-Meier analysis. Receiver operating characteristic curve analysis was calculated to find the optimal sensitivity, specificity, and cutoff values of the variables. The reproducibility of the results obtained was verified in a different but related group of patients.

Results

56 patients (28.7%) had re-bleeding within 6 weeks; HCCPHTIS was an independent risk factor for variceal re-bleeding after AVB (Odd ratio, 2.330; 95% confidence interval: 1.728–3.142, p < 0.001). The positive predictive value of HCCPHTIS cut off value > 3 was 66.2%, sensitivity 83.9%, and specificity 82.3%. HCCPHTIS area under the curve was higher than Child-Pugh score (89% vs. 75%, p < 0.001). 74(37.9%) death occurred within 6 weeks; HCCPHTIS > 4 was associated with increased risk of death within 6 weeks after AVB (p < 0.001).

Conclusion

HCCPHTIS > 3 is a strong predictor of variceal re-bleeding within the first 6 weeks. However, patients with HCCPHTIS > 4 were at increased risk of death within 6 weeks.
Appendix
Available only for authorised users
Literature
1.
go back to reference Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma. Nat Reviews Disease Primers. 2021;7(1):6.CrossRefPubMed Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma. Nat Reviews Disease Primers. 2021;7(1):6.CrossRefPubMed
2.
go back to reference Lang BH, Poon RT, Fan ST, Wong J. Outcomes of patients with hepatocellular carcinoma presenting with variceal bleeding. Am J Gastroenterol. 2004;99(11):2158–65.CrossRefPubMed Lang BH, Poon RT, Fan ST, Wong J. Outcomes of patients with hepatocellular carcinoma presenting with variceal bleeding. Am J Gastroenterol. 2004;99(11):2158–65.CrossRefPubMed
3.
go back to reference Giannini EG, Risso D, Testa R, Trevisani F, Di Nolfo MA, Del Poggio P, et al. Prevalence and prognostic significance of the presence of esophageal varices in patients with hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2006;4:1378–84.CrossRefPubMed Giannini EG, Risso D, Testa R, Trevisani F, Di Nolfo MA, Del Poggio P, et al. Prevalence and prognostic significance of the presence of esophageal varices in patients with hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2006;4:1378–84.CrossRefPubMed
4.
go back to reference Thabut D, Kudo M. Treatment of portal hypertension in patients with HCC in the era of Baveno VII. J Hepatol. 2023;78(3):658–62.CrossRefPubMed Thabut D, Kudo M. Treatment of portal hypertension in patients with HCC in the era of Baveno VII. J Hepatol. 2023;78(3):658–62.CrossRefPubMed
5.
go back to reference Lim J, Kim HI, Kim E, Kim J, An J, Chang S, et al. Variceal bleeding is aggravated by portal venous invasion of hepatocellular carcinoma: a matched nested case-control study. BMC Cancer. 2021;21(1):11.CrossRefPubMedPubMedCentral Lim J, Kim HI, Kim E, Kim J, An J, Chang S, et al. Variceal bleeding is aggravated by portal venous invasion of hepatocellular carcinoma: a matched nested case-control study. BMC Cancer. 2021;21(1):11.CrossRefPubMedPubMedCentral
6.
go back to reference Garcia-Tsao G, Sanyal AJ, Grace ND, Carey W. Practice Guidelines Committee of the American Association for the Study of Liver Diseases the Practice Parameters Committee of the American College of Gastroenterology. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology. 2007;46:922–38.CrossRefPubMed Garcia-Tsao G, Sanyal AJ, Grace ND, Carey W. Practice Guidelines Committee of the American Association for the Study of Liver Diseases the Practice Parameters Committee of the American College of Gastroenterology. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology. 2007;46:922–38.CrossRefPubMed
7.
go back to reference de Franchis R, Baveno VI, Faculty. Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015;63(3):743–52.CrossRefPubMed de Franchis R, Baveno VI, Faculty. Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015;63(3):743–52.CrossRefPubMed
8.
go back to reference de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C. Baveno VII-renewing consensus in portal hypertension. J Hepatol. 2022;76(4):959–74.CrossRefPubMed de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C. Baveno VII-renewing consensus in portal hypertension. J Hepatol. 2022;76(4):959–74.CrossRefPubMed
9.
go back to reference Grgurevic I, Bokun T, Salkic NN, Brkljacic B, Vukeli c-Markovic M, Stoos Veic T, et al. Liver elastography malignancy prediction score for noninvasive characterization of focal liver lesions. Liver Int. 2018;38(6):1055–63.CrossRefPubMed Grgurevic I, Bokun T, Salkic NN, Brkljacic B, Vukeli c-Markovic M, Stoos Veic T, et al. Liver elastography malignancy prediction score for noninvasive characterization of focal liver lesions. Liver Int. 2018;38(6):1055–63.CrossRefPubMed
10.
go back to reference Haemmerle M, Stone RL, Menter DG, Afshar-Kharghan V, Sood AK. The platelet lifeline to cancer: challenges and opportunities. Cancer Cell. 2018;33(6):965–83.CrossRefPubMedPubMedCentral Haemmerle M, Stone RL, Menter DG, Afshar-Kharghan V, Sood AK. The platelet lifeline to cancer: challenges and opportunities. Cancer Cell. 2018;33(6):965–83.CrossRefPubMedPubMedCentral
11.
go back to reference Pavlovic N, Rani B, Gerwins P, Heindryckx F. Platelets as key factors in Hepatocellular Carcinoma. Cancers (Basel). 2019;11(7):1022.CrossRefPubMed Pavlovic N, Rani B, Gerwins P, Heindryckx F. Platelets as key factors in Hepatocellular Carcinoma. Cancers (Basel). 2019;11(7):1022.CrossRefPubMed
12.
go back to reference Lai Q, Vitale A, Manzia TM, Foschi FG, Levi Sandri GB, Gambato M, et al. Platelets and Hepatocellular Cancer: bridging the bench to the clinics. Cancers (Basel). 2019;11(10):1568.CrossRefPubMed Lai Q, Vitale A, Manzia TM, Foschi FG, Levi Sandri GB, Gambato M, et al. Platelets and Hepatocellular Cancer: bridging the bench to the clinics. Cancers (Basel). 2019;11(10):1568.CrossRefPubMed
13.
go back to reference Nadarevic T, Giljaca V, Colli A, Fraquelli M, Casazza G, Miletic D, et al. Computed tomography for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease. Cochrane Database Syst Cochrane Database Syst Rev. 2021;10(10):CD013362.PubMed Nadarevic T, Giljaca V, Colli A, Fraquelli M, Casazza G, Miletic D, et al. Computed tomography for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease. Cochrane Database Syst Cochrane Database Syst Rev. 2021;10(10):CD013362.PubMed
14.
go back to reference Lee JM, Yoon JH, Kim KW. Diagnosis of hepatocellular carcinoma: newer radiological tools. Semin Oncol. 2012;39:399–409.CrossRefPubMed Lee JM, Yoon JH, Kim KW. Diagnosis of hepatocellular carcinoma: newer radiological tools. Semin Oncol. 2012;39:399–409.CrossRefPubMed
15.
go back to reference Kim SH, Kim YJ, Lee JM, Choi KD, Chung YJ, Han JK, et al. Esophageal varices in patients with cirrhosis: Multidetector CT esophagography comparison with endoscopy. Radiology. 2007;242:759–68.CrossRefPubMed Kim SH, Kim YJ, Lee JM, Choi KD, Chung YJ, Han JK, et al. Esophageal varices in patients with cirrhosis: Multidetector CT esophagography comparison with endoscopy. Radiology. 2007;242:759–68.CrossRefPubMed
16.
go back to reference Shang Wan Y, He X, Zhang Y, Wei B, Song. Quantitative measurements of esophageal varices using computed tomography for prediction of severe varices and the risk of bleeding: a preliminary study. Insights Imaging. 2022;13(1):47.CrossRefPubMedPubMedCentral Shang Wan Y, He X, Zhang Y, Wei B, Song. Quantitative measurements of esophageal varices using computed tomography for prediction of severe varices and the risk of bleeding: a preliminary study. Insights Imaging. 2022;13(1):47.CrossRefPubMedPubMedCentral
17.
go back to reference Toshihiro Kawai Y, Yashima T, Sugimoto T, Sato, Shuntaro Obi. Emergency endoscopic variceal ligation following variceal rupture in patients with advanced hepatocellular carcinoma and portal vein tumor thrombosis: a retrospective study. World J Surg Oncol. 2016;14:52.CrossRefPubMedPubMedCentral Toshihiro Kawai Y, Yashima T, Sugimoto T, Sato, Shuntaro Obi. Emergency endoscopic variceal ligation following variceal rupture in patients with advanced hepatocellular carcinoma and portal vein tumor thrombosis: a retrospective study. World J Surg Oncol. 2016;14:52.CrossRefPubMedPubMedCentral
18.
go back to reference Ikai I, Kudo M, Arii S, Omata M, Kojiro M, Sakamoto M, et al. Report of the 18th follow-up survey of primary liver cancer in Japan. Hepatol Res. 2010;40:1043–59.CrossRefPubMed Ikai I, Kudo M, Arii S, Omata M, Kojiro M, Sakamoto M, et al. Report of the 18th follow-up survey of primary liver cancer in Japan. Hepatol Res. 2010;40:1043–59.CrossRefPubMed
19.
go back to reference Sun J, Guo R, Bi X, Wu M, Tang Z, Lau WY, et al. Guidelines for diagnosis and Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus in China (2021 Edition). Liver Cancer. 2022;17(4):315–28.CrossRef Sun J, Guo R, Bi X, Wu M, Tang Z, Lau WY, et al. Guidelines for diagnosis and Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus in China (2021 Edition). Liver Cancer. 2022;17(4):315–28.CrossRef
20.
go back to reference Bruix J, Chan SL, Galle PR, Rimassa L, Sangro B. Systemic treatment of hepatocellular carcinoma: an EASL position paper. J Hepatol. 2021;75(4):960–74.CrossRefPubMed Bruix J, Chan SL, Galle PR, Rimassa L, Sangro B. Systemic treatment of hepatocellular carcinoma: an EASL position paper. J Hepatol. 2021;75(4):960–74.CrossRefPubMed
21.
go back to reference Rizzo A, Ricci AD, Brandi G. Systemic adjuvant treatment in hepatocellular carcinoma: tempted to do something rather than nothing. Future Oncol. 2020;16(32):2587–9.CrossRefPubMed Rizzo A, Ricci AD, Brandi G. Systemic adjuvant treatment in hepatocellular carcinoma: tempted to do something rather than nothing. Future Oncol. 2020;16(32):2587–9.CrossRefPubMed
22.
go back to reference Rizzo A, Ricci AD, Brandi G. Atezolizumab in advanced hepatocellular carcinoma: good things come to those who wait. Immunotherapy. 2021;13(8):637–44.CrossRefPubMed Rizzo A, Ricci AD, Brandi G. Atezolizumab in advanced hepatocellular carcinoma: good things come to those who wait. Immunotherapy. 2021;13(8):637–44.CrossRefPubMed
23.
go back to reference Mollica V, Rizzo A, Marchetti A, Tateo V, Tassinari E, Rosellini M et al. The impact of ECOG performance status on efficacy of immunotherapy and immune-based combinations in cancer patients: the MOUSEION-06 study. Clin Exp Med. 2023; 3. Mollica V, Rizzo A, Marchetti A, Tateo V, Tassinari E, Rosellini M et al. The impact of ECOG performance status on efficacy of immunotherapy and immune-based combinations in cancer patients: the MOUSEION-06 study. Clin Exp Med. 2023; 3.
24.
go back to reference Santoni M, Rizzo A, Mollica V, Matrana MR, Rosellini M, Faloppi L, et al. The impact of gender on the efficacy of immune checkpoint inhibitors in cancer patients: the MOUSEION-01 study. Crit Rev Oncol Hematol. 2022;170:103596.CrossRefPubMed Santoni M, Rizzo A, Mollica V, Matrana MR, Rosellini M, Faloppi L, et al. The impact of gender on the efficacy of immune checkpoint inhibitors in cancer patients: the MOUSEION-01 study. Crit Rev Oncol Hematol. 2022;170:103596.CrossRefPubMed
25.
go back to reference Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358–80.CrossRefPubMed Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358–80.CrossRefPubMed
26.
go back to reference Kim H, Choi D, Gwak GY, Lee JH, Park MK, Lee, HIe, et al. Evaluation of esophageal varices on liver computed tomography: receiver operating characteristic analyses of the performance of radiologists and endoscopists. J Gastroenterol Hepatol. 2009;24:1534–40.CrossRefPubMed Kim H, Choi D, Gwak GY, Lee JH, Park MK, Lee, HIe, et al. Evaluation of esophageal varices on liver computed tomography: receiver operating characteristic analyses of the performance of radiologists and endoscopists. J Gastroenterol Hepatol. 2009;24:1534–40.CrossRefPubMed
27.
go back to reference Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD, et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the study of the liver. Hepatology. 2014;60(2):715–35.CrossRefPubMed Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD, et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the study of the liver. Hepatology. 2014;60(2):715–35.CrossRefPubMed
28.
go back to reference Moreau R, Jalan R, Gines P, Pavesi M, Angeli P, Cordoba J, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology. 2013;144:1426–37.CrossRefPubMed Moreau R, Jalan R, Gines P, Pavesi M, Angeli P, Cordoba J, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology. 2013;144:1426–37.CrossRefPubMed
29.
go back to reference Lerose R, Molinari R, Rocchi E, Manenti F, Villa E. Prognostic features and survival of hepatocellular carcinoma in Italy: impact of stage of disease. Eur J Cancer. 2001;37:239–45.CrossRefPubMed Lerose R, Molinari R, Rocchi E, Manenti F, Villa E. Prognostic features and survival of hepatocellular carcinoma in Italy: impact of stage of disease. Eur J Cancer. 2001;37:239–45.CrossRefPubMed
30.
go back to reference Lipp MJ, Broder A, Hudesman D, Suwandhi P, Okon SA, Horowitz M, et al. Detection of esophageal varices using CT and MRI. Dig Dis Sci. 2011;56(9):2696–700.CrossRefPubMed Lipp MJ, Broder A, Hudesman D, Suwandhi P, Okon SA, Horowitz M, et al. Detection of esophageal varices using CT and MRI. Dig Dis Sci. 2011;56(9):2696–700.CrossRefPubMed
31.
go back to reference Campion B, Larrey E, Wagner M, Rudler M, Thabut D, Allaire M. Portal hypertension, advanced hepatocellular carcinoma and therapy by atezolizumab-bevacizumab: a menage à Trois. Clin Res Hepatol Gastroenterol. 2022;46(2):101785.CrossRefPubMed Campion B, Larrey E, Wagner M, Rudler M, Thabut D, Allaire M. Portal hypertension, advanced hepatocellular carcinoma and therapy by atezolizumab-bevacizumab: a menage à Trois. Clin Res Hepatol Gastroenterol. 2022;46(2):101785.CrossRefPubMed
32.
go back to reference Allaire M, Thabut D. Portal hypertension and variceal bleeding in patients with liver cancer: evidence gaps for prevention and management. Hepatology. 2024;79(1):213–23.CrossRefPubMed Allaire M, Thabut D. Portal hypertension and variceal bleeding in patients with liver cancer: evidence gaps for prevention and management. Hepatology. 2024;79(1):213–23.CrossRefPubMed
33.
go back to reference Irene Conejo MA, Guardascione P, Tandon, et al. Multicenter External Validation of Risk Stratification Criteria for patients with Variceal Bleeding. Clin Gastroenterol Hepatol. 2018;16(1):132–9.CrossRefPubMed Irene Conejo MA, Guardascione P, Tandon, et al. Multicenter External Validation of Risk Stratification Criteria for patients with Variceal Bleeding. Clin Gastroenterol Hepatol. 2018;16(1):132–9.CrossRefPubMed
Metadata
Title
HCC portal hypertension imaging score derived from CT predicts re-bleeding and mortality after acute variceal bleeding
Authors
Mingyuan Zhao
Binyue Zhang
Jianqiang Shi
Xiaoxian Tang
Hongxia Li
Shengwen Li
Yunfeng Yang
Yi Han
Rong Wang
Jian Xun
Kai Zhang
Xirun Wu
Jiang Zhao
Publication date
01-12-2024

Other articles of this Issue 1/2024

Cancer Imaging 1/2024 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine